



Ovid Therapeutics

Corporate Overview

MAY 2023

Disclaimers and forward-looking statements

This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the timing and development of Ovid’s product candidate pipeline and achievement of expected near- and long-term milestones; the potential therapeutic benefits of Ovid’s current or future product candidates and pipeline programs; the reporting of data for the potential Phase 1 study in healthy volunteers for OV329; the potential use of OV329 to treat rare and treatment-resistant forms of epilepsy and seizures; the clinical and regulatory development of OV329, including the anticipated timing of clinical trials of OV329; the likelihood that data for OV329 will support future development and therapeutic potential; the potential development of OV350 and other KCC2 compounds in the Company’s library; the potential timing of a potential IND filing for OV350; the suitability of the Company’s library of novel, direct KCC2 transporter activators for a range of formulations and administrations that would make it possible to pursue both chronic and acute epilepsies; the potential development and therapeutic opportunity of GV101 and other Rho/Rho associated coiled-coil containing protein kinase 2 inhibitors; and the potential safety, selectivity and potency of GV101 and other ROCK2 inhibitors; the potential use of GV101 and other ROCK2 inhibitors to treat cavernous cerebral malformations and other rare central nervous system disorders; the potential timing of the pivotal formulation for GV101; the potential timing of Phase 1 and 2 clinical studies for GV101 and the resulting data; the timing for the completion of Takeda’s two pivotal Phase 3 trials evaluating soticlestat for Lennox-Gastaut and Dravet syndromes; the potential timing of regulatory decisions on soticlestat; the success of Takeda’s trials in soticlestat; the duration of the Company’s cash runway, and the expectation that it will support the advancement of the Company’s pipeline; Ovid’s business development intentions; the success of any licensing or partnering opportunities; the success, timing, ability to attract and maintain strategic collaborations; the clinical and regulatory development and potential commercialization of soticlestat, OV329, OV350, GV101 or any of Ovid’s other current or future product candidates and pipeline programs and market opportunities. You can identify forward-looking statements because they contain words such as “will,” “may,” “plan,” “believes,” “intends,” “anticipates,” “strives,” “design,” “advance,” “target,” “seek,” “expects,” and “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances).

Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid’s ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy, risks related to Ovid’s ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions and risks to Ovid’s or any of its partners’ abilities to meet anticipated deadlines and milestones presented by the ongoing COVID-19 pandemic. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption “Risk Factors” in Ovid’s Quarterly Report of Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 5, 2023, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

The trademarks included in this presentation are the property of the owners thereof and are used for reference purposes only.



©2023 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

2



**Transforming the lives of
individuals with epilepsies
& seizure-related
disorders**



Focused pipeline

in epilepsies & seizure-related disorders that have significant unmet need & large addressable markets



Significant milestones & royalties

due from Takeda surrounding potential regulatory approval & commercial sales of soticlestat



Veteran team

with track record of value creation & transformative transactions



Cash runway expected into first half of 2025

& disciplined approach to business development

Epilepsy market is a significant and growing market

Significant patient need



30 – 40%

of individuals have seizures not controlled with anti-seizure medicines¹



47%

of patients take 5 medicines on average, demonstrating need for unique, well tolerated anti-seizure mechanisms²

Supportive of predictive development



Validated & emerging targets cause neuronal hyperexcitability



Small molecules that can cross the blood-brain barrier



Predictive, clinically-translatable seizure models



Hard endpoints (seizures) and biomarkers

Addressable patient population



50 million

people living with epilepsy worldwide³



3 million

adults and 470,000 children living with epilepsy in US⁴



> \$8B

global market⁵

1. Huron Primary Research (11/2019-12/2019)

2. Terman SW, Aubert CE, Hill CE, et al. Polypharmacy in patients with epilepsy: a nationally representative cross-sectional study. *Epilepsy Behav.* 2020;111:107261.



3. WHO Fact Sheet. Accessed March 12, 2023; <https://www.who.int/news-room/fact-sheets/detail/epilepsy#:~:text=Globally%2C%20an%20estimated%205%20million,as%20139%20per%20100%20000>.

4. CDC Epilepsy data: <https://www.cdc.gov/epilepsy/data/index.html>

5. Global Data Report, Epilepsy: Global Drug Forecast and Market Analysis to 2030 – Forecast Update

Advancing differentiated epilepsy & seizure programs

First-in-class or best-in-class mechanisms of action

EPILEPSY PROGRAMS	INDICATION/TARGET	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	ANTICIPATED MILESTONES
SOTICLESTAT Cholesterol 24-hydroxylase inhibitor Out-licensed to 	Dravet syndrome					Phase 3 data from 2 registrational trials
	Lennox-Gastaut syndrome					Filing marketing authorization submissions in Takeda's FY 2024
GV101*  Selective ROCK2 inhibitor Collaboration with 	Brainstem cavernous malformations Undisclosed indications					- MAD initiation H2 2023 - Phase 2 FPI 2024
OV329 GABA-aminotransferase inhibitor In-licensed from: 	Tuberous sclerosis complex, infantile spasms and focal seizures					Phase 1 target engagement & safety in H1 2024
OV350 & KCC2 PORTFOLIO KCC2 transporter activator In-licensed from: 	Resistant epilepsies and other neuropathologies					IND in 2024
UNDISCLOSED ROCK2 INHIBITOR PROGRAMS						

*Graviton is conducting development of GV101 through Phase 2 and such development will be directed by a Joint Development Committee that includes members of both Graviton and Ovid.

Progress & near-term milestones

Long-term vision

- **A leading anti-seizure franchise** with differentiated medicines to serve a portion of >\$8B market
- **Fully integrated biotech company** with multiple commercial & clinical stage CNS programs
- **Strategic business development** to reach global epilepsy market opportunity

Recent accomplishments

- **Repurchase of soticlestat** by Takeda for Dravet & Lennox-Gastaut syndromes (LGS), with \$196M upfront payment; and up to: \$660M in milestones and 20% royalties
- **In-licensed KCC2** portfolio to strengthen epilepsy franchise from AstraZeneca
- **NEW:** Initiated collaboration to develop ROCK2 inhibitors in rare CNS with Graviton; in-licensing clinical-stage & preclinical compounds
- **Initiated Phase 1 trial** of OV329
- **Streamlined company** to preserve strong cash position to support corporate goals
- **Bolstered management team** with experts in epilepsy development

Near-term milestones

- **NEW:** GV101 pivotal formulation & MAD data expected in H2 2023
- **Phase 3 data of soticlestat** in Dravet & LGS anticipated *prior* to global regulatory filings by Takeda in its FY 2024
- **OV329 Phase 1 SAD & MAD data** expected in H1 2024
- **Anticipated IND submission** for KCC2 portfolio (OV350) in 2024

Team of disciplined operators & value creators



Jeremy Levin
D. Phil, MB BChir
Chairman, CEO



Julia Tsai, Ph.D.
Head, Clinical
Development
& Medical



Claude Nicaise, M.D.
Head, Research
& Development



Manoj Malholtra, M.D.
Chief Medical Officer



Jeffrey Rona
Chief Business &
Financial Officer



Jason Tardio, MBA
Chief Operating Officer



Tom Perone,
MBA, J.D.
General Counsel,
Corporate Secretary,
Chief Compliance Officer



Meg Alexander
Chief Strategy & Corporate
Affairs Officer



- ✓ **Transformative transactions**
Invested ~\$83M in soticlestat, which secured \$196M in upfront payment & potential milestones of up to \$660M and tiered royalties of up to 20%
- ✓ **Track record of expedited development**
Completed soticlestat Phase 2 six months ahead of schedule and under budget
- ✓ **Experience from 25+ launches, including 4 CNS blockbusters**
- ✓ **Deep knowledge from development & launch of multiple epilepsy medicines**

Contributed to development & launch:

TYSABRI
(natalizumab)

Ztalmey
(ganaxolone)
oral suspension 50 mg/mL

GILENYA
(fingolimod) 120mg capsules

Revlimid
(lenalidomide) capsules
10, 25, 50, 75, 100 mg

SPRYCEL
dasatinib 25, 50, 75, 100 mg tablets

Fintepla
(fenfluramine) 2.2 mg/mL oral solution

Brineura
(cerliponase alfa)

SPINRAZA
(nusinersen) injection 10 mg/mL

Tecfidera
(dimethyl fumarate) delayed-release capsules 240mg

REPURCHASED BY TAKEDA

OVERVIEW: soticlestat

Potential first-in-class cholesterol 24-hydroxylase inhibitor for treatment resistant epilepsies¹


Being studied in two pivotal, Phase 3 trials

(conducted by Takeda):

- Dravet syndrome (DS)
- Lennox-Gastaut syndrome (LGS)

Designed to reduce seizure susceptibility & improve seizure control²

Unique mechanism of action



- Reduces glutamatergic signaling & reduced inflammation^{1,3}
- Dose dependent response^{1,3}

Encouraging safety, tolerability & seizure reduction in Phase 2 trials²

- Main adverse events for soticlestat over placebo are lethargy/somnolence and constipation
- No anticipated monitoring needs

Potential to be used in early treatment lines²

- Based upon promise of seizure control efficacy and tolerability profile observed in clinical trials
- No monitoring anticipated for soticlestat as is required for other new anti-seizure medicines⁴

Takeda targets filing for regulatory approvals in its fiscal year 2024⁴

1. Nishi T, et al. AAN 2018.

2. Hahn et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA). Epilepsia. 2022; 00: 1–13. <https://doi.org/10.1111/epi.17367>

3. Salamone A, et al. ECE 2018 ⁴ FINTEPLA prescribing information label, pages 5-8.

4. Takeda's FY2022 Q2 Earnings Announcement dated October 27th, 2022.

New long-term analysis supports soticlestat safety, tolerability & seizure reduction profile

Presented at American Academy of Neurology 2023¹

- 2-year (interim) analysis of ENDYMION 1, an open-label extension study of patients with DS or LGS who rolled over from the Phase 2 ELEKTRA trial
- Sought to evaluate the long-term safety and tolerability of soticlestat as well as efficacy as an adjunctive therapy to standard treatment
- Patient disposition measured as of May 31, 2022


Up to 2-years of treatment, soticlestat was:

- Generally well tolerated
- Majority of TEAEs were mild or moderate in severity
- Drug-related TEAEs occurring in $\geq 5\%$ of patients were decreased appetite (10.0%), seizure (7.7%), and somnolence (7.7%)
- Demonstrated a sustained reduction in frequency of convulsive (DS) and drop (LGS) seizures from baseline
- Showed sustained reduction in “all seizure” frequency


SOURCE: Long-Term Treatment Effects of Soticlestat in Patients with Dravet Syndrome or Lennox–Gastaut Syndrome: Interim Data from the ENDYMION 1 Trial as presented at AAN: <https://www.aan.com/MSA/Public/Events/AbstractDetails/52787>

Sustained seizure reduction demonstrated in analysis of DS & LGS patients up to 2 years

REDUCTION IN FREQUENCY OF CONVULSIVE SEIZURES FOR DS & DROP SEIZURES FOR LGS



REDUCTION IN ALL SEIZURE FREQUENCY



SOTICLESTAT DEMONSTRATED UP TO 2-YEARS OF TREATMENT AND:

- Contributed to a sustained reduction in convulsive seizures in DS patients and drop seizures in LGS patients, which are similar endpoints being used in two pivotal Phase 3 trials ongoing in the same epilepsies
- Was associated with a reduced seizure frequency up to 2 years of treatment

Ongoing Phase 3 placebo-controlled studies in Dravet & Lennox-Gastaut syndromes

Trials currently being conducted by Takeda

soticlestat

SKYLINE: DS N = 142

SKYWAY: LGS N = 234

Soticlestat BID
(Add-on to SoC)

Placebo BID
(Add-on to SoC)

Entry into OLE

Titration (4 weeks)¹

Maintenance (12 weeks)

Full treatment period 16 weeks

TRIAL DESIGN

- Trial design based on feedback from FDA, EMA & PMDA
- Ages ≥ 2 years
- Adjunctive to ASMs
- Active seizures at baseline²

OUTCOME MEASURES

Primary

- Frequency change in convulsive seizures (DS study) during full treatment period
 - DS: ≥ 4 convulsive seizures at baseline
- LGS study uses **Major Motor Drop seizure endpoint** (frequency change in major motor drop seizures) during full treatment period
 - LGS: ≥ 8 Major Motor Drop (MMD) seizures at baseline.
 - For LGS, countable drop seizures reliably recognized by the caregivers and consistently implemented by the investigators

¹100 mg BID, 200 mg BID, 300 mg BID (mg/kg dosing)

²Clinical Trials.gov Accessed October 26, 2021.

Status update: Soticlestat registrational trials

As of April 12, 2023



A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

109 sites worldwide¹

86 active recruiting • 13 expected to be recruiting



A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

96 sites worldwide¹

73 active and recruiting • 13 expected to be recruiting

TAKEDA guides to regulatory filings in its fiscal year 2024 (begins April 2024); following Phase 3 data for both indications

¹ Clinical Trials.gov updates as of April 12, 2023. Approximately 10 sites in Russia and Ukraine are considered "active; not recruiting."

Skyway: <https://clinicaltrials.gov/ct2/show/NCT04938427>

Skyline: <https://clinicaltrials.gov/ct2/show/NCT04940624>

Soticlestat agreement with Takeda holds value of up to \$856M¹, creating a potential non-dilutive cash stream

Invested ~\$26M upfront & \$57M in clinical development

2021	2025*	Est. 2025 and later
Upfront payment All Ovid financial obligations for soticlestat are terminated	Expected regulatory decision milestone(s) - Takeda funding comprehensive LGS and Dravet trials - Soticlestat is leading neuroscience Phase 3 program for Takeda²	Commercial milestones & royalties - Tiered double-digit royalties on ALL indications - Up to 20% on GLOBAL soticlestat sales
\$196M (Q1'21)	Up to \$660M in additional milestones⁺ + Royalties (up to 20%) ⁺ Potential for combined regulatory and commercial milestone payments	
ROYALTY & MILESTONES TO FUND PIPELINE & BUSINESS DEVELOPMENT		

Estimated timing based on Takeda disclosure that it anticipates regulatory filings in its fiscal year 2024.

¹ \$856M includes the \$196M already received as an upfront payment in 1H 2021

² Takeda Consolidated Development Pipeline by Phase Presentation. Accessed November 2022.

NEW

COLLABORATION WITH GRAVITON

OVERVIEW: GV101 & ROCK2 inhibitor library

Potent, highly selective inhibitors of Rho/Rho associated coiled-coil containing protein kinase 2 (ROCK2) for cerebral cavernous malformations¹

GV101

GV101, best-in-class potential

- More selective for ROCK2 than Rezurock,[®] REDX10843, NRL-1049^{2,3}
- Well characterized safety profile (2 Phase 1 studies)
- Blood-brain barrier penetrant³

Completed Phase 1 dosing

- Extensive preclinical safety & toxicology
- Completed dosing of Phase 1 SAD/MAD in China (nano-suspension)
- Modeled therapeutic plasma levels have been shown to be generally well tolerated
- Cmax values up to 2 µg/mL

Novel mechanism; rationale in multiple CNS indications

- ROCK2 is a signaling pathway that acts on actin cytoskeletal processes, cellular to extracellular matrix adhesion, fibrosis, autoimmunity
- Fit for CNS conditions with endothelial dysfunction & autoimmune MoAs

Regulatory precedent

- Prior ROCK2 regulatory approvals (Rezurock[®] in GVHD)
- Potential to leverage orphan and/or accelerated approval programs

Studying desired pivotal formulation (gel capsule) in a Phase MAD study

¹ Based upon animal models | ² *Ann Clin Transl Neurol*. 2014 Jan; 1(1): 2–14. Published online 2013 Nov 19. doi: [10.1002/acn3.19](https://doi.org/10.1002/acn3.19) | ³ <https://patents.google.com/patent/US10106525B2/en> | Graviton data on file

Transaction terms with Graviton

A collaboration with former founders of KADMON

Exclusivity to a library of compounds

Exclusive rare CNS rights to the lead asset (GV101) and ~12 other ROCK2i's optimized for CNS penetration & exposure

Upfront investment

\$10 million in the current preferred equity round of ~\$50–\$60M

Equity opportunity

Economic upside in a broad range of ROCK2 inhibitor indications beyond CNS

Milestone payments

No milestone payments

Royalties in the mid-to-upper teens payable to Graviton under the agreement, on net sales

Development & commercialization

Graviton conducts development through the end of Phase 2; under the License Agreement such development plans are to be mutually agreed on by the parties through the JDC

Ovid will fund the development through agreed upon budgets and has decision-making authority

Development and commercialization responsibility will be handed over to Ovid post-Phase 2




ROCK2 inhibition in the CNS

ROCK1 and ROCK2 are highly homologous isoforms of the ROCK protein kinase that function differently

- ROCK inhibitors to-date have relatively equipotent inhibition against ROCK1 and ROCK2 isoforms
- Toxicity is associated with pan-ROCK inhibition, notably hypotension

In the CNS, ROCK2 inhibition has the potential to:

- Promote growth and the cell-to-cell junction formation that is critical to endothelial function^{1,2}
- In neurons, is associated with increased neurite growth and decreased cell death



A – B. Miller KE, Suter DM. An Integrated Cytoskeletal Model of Neurite Outgrowth. Front Cell Neurosci. 2018 Nov 26;12:447. Adapted from O'Toole et al. (2015) with permission from Elsevier

C. Gibieža P, Petrikaitė V. The regulation of actin dynamics during cell division and malignancy. Am J Cancer Res. 2021 Sep 15;11(9):4050-4069.

1. McKerracher L; et. al. Translational Stroke Research (2020) 11:365-376

2. Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, Johnson GL. Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. J Biol Chem. 2010 Apr 16;285(16):11760-4. doi: 10.1074/jbc.C109.097220.

GV101 1st intended indication: Brainstem cavernous malformations

GV101

A potent and highly selective inhibitor of ROCK2 for potential treatment of lesions located in the brainstem of people with cavernous malformations¹

Why CCM?

- Mechanistic rationale for reversing hyperactivity of ROCK; restoring barrier function and endothelial cell junctions²
- Animal model proof-of-concept in ROCK2 inhibitors³
- Unmet need; rare, acute disease with no approved therapy
- Potential to gain POC with subset prior to a larger registrational trial
- Will pursue measurable endpoints (radiographic)
- Possibility of accelerated path to market

Large population with great need

**Total patients (prevalence)
1.6M⁴**

**CCM patients with
symptoms
960K⁵**

**Brainstem
involvement
~190K⁶**

1. Ovid data on file | 2. Stockton RA, Shenkar R, Awad IA, Ginsberg MH. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med. 2010 Apr 12;207(4):881-96. doi: | 3 McKerracher L.; et. al. Translational Stroke Research (2020) 11:365-376 | 4. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924279/pdf/nihms-1059977.pdf> | 5. <https://www.ncbi.nlm.nih.gov/books/NBK1293/> | 6. Otten P, Pizzolato GP, Rilliet B, Berney J. [131 cases of cavernous angioma (cavernomas) of the CNS, discovered by retrospective analysis of 24,535 autopsies]. Neurochirurgie. 1989;35(2):82-3, 128-31.

Brainstem cavernous malformations

Presentation & prevalence

- Mulberry-shaped abnormal blood vessels with thin, leaky walls located in the brain and or spinal cord, which increase over age
- 2nd most common intracranial vascular malformation in humans^{1,2}

CCMs located in the brainstem pose unique challenges

- Brainstem CCMs are a key risk factor for brain bleeds, can cause significant morbidity due to repeated hemorrhaging³
- 82% of patients with brainstem lesions involve major fiber tracts, making surgery extremely difficult³
- Guidelines indicate that surgical resection of brainstem CCM could be considered only after a second symptomatic bleed given risks associated with the surgery⁴
 - Post operative mortality and morbidity are high among patients who undergo surgery to remove brainstem lesions⁴
 - 53% of the cases experience post operative neurologic deficits²




Image attribution: Brainstem angioma from Alliance to Cure Cavernous Malformation

1. Zafar A, Quadri SA, Farooqui M, Ikram A, Robinson M, Hart BL, Mabray MC, Vigil C, Tang AT, Kahn ML, Yonas H, Lawton MT, Kim H, Morrison L. Familial Cerebral Cavernous Malformations. Stroke. 2019 May;50(5):1294-1301. doi: 10.1161/STROKEAHA.118.022314. PMID: 30909834; PMCID: PMC6924279 | 2. Caton MT, Shenoy VS. Cerebral Cavernous Malformations. [Updated 2022 Oct 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK538144/>. | 3. Ma L, Zhang S, Li Z, Wu CX, Wang Z, Zhan L, Hao Q, Wang H, Ye X, Chen X, Liu YQ, Wang S, Zhao YL. Morbidity After Symptomatic Hemorrhage of Cerebral Cavernous Malformation: A Nomogram Approach to Risk Assessment. Stroke. 2020 Oct;51(10):2997-3006. doi: 10.1161/STROKEAHA.120.029942. Epub 2020 Sep 21. PMID: 32951540. | 4. Akers A, Al-Shahi Salman R, A Awad I, Dahlem K, Flemming K, Hart B, Kim H, Jusue-Torres I, Kondziolka D, Lee C, Morrison L, Rigamonti D, Rebeiz T, Tournier-Lasserre E, Waggoner D, Whitehead K. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery. 2017 May 1;80(5):665-680. doi: 10.1093/neuros/nyx091. PMID: 28387823; PMCID: PMC5808153.

ROCK2 inhibitor initial development strategy

1 Demonstrate CNS penetration and characterize safety

2 MAD study to confirm pivotal formulation

3 Proof-of-concept demonstration in high-need subset: brain stem hemangiomas

- Target: Patients with cavernous angioma in the brainstem

4 Pivotal study (Brainstem or familial cavernous malformations)

OVERVIEW: **OV329**

A potential best-in-class GABA-aminotransferase inhibitor for treatment of rare adult & pediatric epilepsy disorders

OV329's enhanced potency may deliver:

- Increased seizure reduction efficacy
- Improved safety profile (better ocular safety margin than vigabatrin in preclinical studies)
- Preferred dosing

Demonstrated anti-seizure activity in 6 separate animal models

Multiple possible applications:

- Seizures associated with tuberous sclerosis complex (TSC)
- Infantile spasms
- Conditions with focal seizures

Phase 1 study ongoing

- Findings including potential indicator of efficacy & safety expected H1 2024


A potent, next-generation GABA AT-inhibitor

OV329


Believed to act upon a validated anti-seizure target to increase GABA and reduce neuronal hyperexcitability

- More potent than vigabatrin in preclinical testing
- Potentially improved safety profile
- Anticipated lower dosing than vigabatrin will be needed


Vigabatrin



OV329



SOURCE:
¹Juncosa, JI et al. *J. Am Chem. Soc.* 2018;140(6):2151-2164;
J Med Chem. 2012 Jan 26; 55(2): 567-575
J Am Chem Soc. 2018 Feb 14; 140(6): 2151-2164
 J. Tsai, EILAT 2023 presentation



Need for next-generation GABA-AT inhibitors

Sabril (vigabatrin) is only approved GABA-AT inhibitor

- Approved in 2009
- 1st line treatment for certain forms of infantile spasms, including seizures associated with tuberous sclerosis complex¹
- Effective seizure reduction, but no therapeutic window²
- Post-approval, use of vigabatrin was associated with progressive visual field loss from retinal toxicity³
 - Deterred use
 - REMS

Significant market opportunity



Sabril peak sales in U.S.
(Not representative of global sales)⁴

Underserved patient populations

Prevalence: Tuberous sclerosis complex

~1 in 6,000 live births^{5,6}



As many as 2 million people worldwide are believed to have disorder

~40,000 to 80,000 people in the U.S. have TSC

Seizures are the most common neurological features of TSC (occur in ~85%)⁷

Prevalence: Infantile spasms

1.6-4.5 cases per 10,000 live births in the U.S.

~2,000 to 2,500 new cases in U.S. per year⁸



¹ Pesaturo KA, Spooner LM, Belliveau P. Vigabatrin for infantile spasms. *Pharmacotherapy*. 2011 Mar;31(3):298-311. doi: 10.1592/phco.31.3.298. PMID: 21361740.

² Maguire et al., 2010; *Epilepsia*, 51(12):2423-2431, 2010

³ BMJ 1997;314:180-181

⁴ IMS sales of oral solution vigabatrin 2017

⁵ Osborne, JP et al. *Lancet*. 2000;355(9216):1698 P;615:125

⁶ Hong, CH et al. *Br J Dermatol*. 2016;174(6):1282-1289

⁷ Kingswood, JC et al. *Orphanet J Rare Dis*. 2017;12(1):2

⁸ Wheless, JW et al. *BMC Pediatr*. 2012;12:108;


Six preclinical models reaffirm OV329 seizure reduction activity, including resistant seizure models¹

	6 Hz Electrical Stimulation	Maximal Electroshock (MES)	i.v. Pentylentetrazol (ivPTZ)	NMDA-Induced Infantile Spasm Model	Audiogenic Seizure	Amygdala Kindled	Corneal Kindled	Intrahippocampal Kainate Model of Mesial-Temporal Lobe Epilepsy (MTLE)
Injury Model	Acute/seizure	Acute/seizure	Acute/seizure	Acute/seizure	Acute	Chronic/epilepsy	Chronic/epilepsy	Chronic/epilepsy
Clinical Correlate	Acute focal to bilateral tonic-clonic seizure	Generalized tonic-clonic seizure	Nonconvulsive seizures (eg absence, myoclonic)	Infantile spasms	Generalized seizures	Chronic focal to bilateral tonic-clonic seizure/ Pharmacoresistant seizures	Chronic focal to bilateral tonic-clonic seizure	Mesial temporal lobe epilepsy/ Pharmacoresistant seizures
Species	Mouse	Mouse	Rat	Mouse	Mouse	Rat	Mouse	Mouse
Dosing	Acute (0.01, 0.1, 0.3, 1 mg/kg/day, p.o.)	Acute (1, 3, 10, 30 mg/kg, p.o.)	Acute (5, 20, 40 mg/kg i.p.)	Acute (0.0025, 0.01, 0.1, 1 mg/kg, p.o.)	Acute (0.01, 0.05, 0.1 mg/kg, p.o.)	Acute (30, 40 mg/kg, i.p.)	Acute (1, 3, 10, 20, 30, 40, 60 mg/kg, p.o.)	Acute, single dose (0.01, 0.1, 1, 10 mg/kg, p.o.; 10 mg/kg, i.p.) Subacute (8 days q.d.) 0.3, 1.0 and 3.0 mg/kg/day (p.o.)
Activity	—	—	+	+	+	+	+	+


1. Ovid data on file

No ocular effects seen following chronic exposure with OV329 (3 mg/kg)


Vehicle



OV329 3.0 mg/kg



Vigabatrin 300 mg/kg



No ocular effects seen in 3 mg/kg OV329, q.d. and vehicle groups in rats at Day 45

Ocular effects seen in more than half of rats treated with Vigabatrin (300 mg/kg)

Ongoing Phase 1 study

Design

Single (Part 1) and multiple (Part 2) ascending dose studies gated by cohort

Conducted at Duke University School of Medicine

Healthy volunteers (6 active; 2 placebo)

8 volunteers per cohort

Target engagement measured by magnetic resonance spectrometry (MRS)

Levels of target engagement, as measured by MRS, have been correlated to therapeutic effect in prior GABA-AT inhibitors.^{1, 2, 3}

Safety, tolerability and pharmacokinetic characterization of single and multiple doses of OV329

1. Petroff OA, Rothman DL, Behar KL, Collins TL, Mattson RH. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. *Neurology*. 1996 Dec;47(6):1567-71. doi: 10.1212/wnl.47.6.1567. PMID: 8960747.

2. Petroff OA, Rothman DL, Behar KL, Mattson RH. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. *Neurology*. 1996 May;46(5):1459-63. doi: 10.1212/wnl.46.5.1459. PMID: 8628502.

3. Prescott AP, Miller SR, Ingenito G, Huber RS, Kondo DG, Renshaw PF. In Vivo Detection of CPP-115 Target Engagement in Human Brain. *Neuropsychopharmacology*. 2018 Feb;43(3):646-654. doi: 10.1038/npp.2017.156. Epub 2017 Jul 25. PMID: 28741622; PMCID: PMC5770752.

OVERVIEW: OV350 & KCC2 portfolio

Potential first-in-
class direct
activators of the
KCC2 transporter

Innovative KCC2 program

- Consulting support by neuropharmacologist, Prof. Steve Moss
- Chemistry & lead identification conducted by AstraZeneca

Novel mechanism of action

- Only known direct KCC2 activator
- Measurable with biomarker (EEG high gamma power spectrum)¹

Does not induce sedation¹

in preclinical models

Franchise in a program

- OV350 & compound library
- Individual compounds potentially suitable for:
 - IV – acute indications
 - Oral – chronic needs

Broad therapeutic potential in rare & common populations including:


- Genetic epilepsies
- Acute epilepsies
- Neuropathic pain
- Behavioral & cognitive conditions

Preclinical proof of concept demonstrated in-vivo & in-vitro in resistant seizures and other CNS indications¹

¹ Jarvis et al., 2023, Cell Reports Medicine 4, 100957, March 21, 2023


OV350 preclinical models show rapid, stable accumulation in the brain with a translatable pharmacodynamic biomarker¹

KCC2 is expressed exclusively in neurons, unlike other K/Cl co-transporters




1. Ovid data on file

OV350 rapidly accumulates in rodent brain via IV/IP dosing




OV350 induces a shift in EEG high gamma power spectrum (biomarker)




- OV350 in-vivo pharmacokinetics shows high micromolar accumulation in the brain within minutes
- Highly translatable EEG pharmacodynamic biomarker confirmed in healthy animals¹

KCC2 transporter is central to regulating neuronal inhibition, potentially reducing seizures¹


Healthy Neuron



Epileptic Neuron




Potential Effect of OV350



¹ Illustrations adapted from publication by Phan Q. Duy, Miao He, Zhigang He & Kristopher T. Kahle (2020) Preclinical insights into therapeutic targeting of KCC2 for disorders of neuronal hyperexcitability, Expert Opinion on Therapeutic Targets, 24:7, 629-637, DOI: 10.1080/14728222.2020.1762174


In-vivo studies demonstrate mechanistic proof of concept

OV350 restores the efficacy of diazepam to terminate “refractory” *Status Epilepticus* in preclinical study




- Potentiating KCC2 activity observed to be well tolerated in-vivo
- Unlike other anticonvulsants, OV350 appears to not induce sedation

Experimental design



Post-treatment EEG analysis



Source: Jarvis et al., 2023, Cell Reports Medicine 4, 100957, March 21, 2023

Development focus with OV350

Clinically suitable formulation

IV formulation candidate suitable for clinical trials achieved for OV350

Demonstrated anti-seizure activity in iPTZ and kainite status epilepticus models

Publication of findings in *Cell Reports Medicine* March 2023¹

Characterization efforts of OV350 ongoing in seizure and other CNS models

Further formulation and characterization of additional compounds in KCC2 portfolio ongoing

Efforts seek to achieve oral and IV formulations

¹ Jarvis et al., 2023, *Cell Reports Medicine* 4, 100957, March 21, 2023

Investment highlights

+ Strong balance sheet

\$117.7M

in cash, cash equivalents and marketable securities¹

70.5M

shares of common stock outstanding²

Current cash runway expected into first half of 2025

Potential for a non-dilutive capital stream from Takeda

+ Veteran team

with a track record of developing and commercializing blockbuster medicines

+ Differentiated epilepsy franchise

- 3 small molecule programs (4th program sold to Takeda and we retain significant financial interest)
- Potential 1st-in-class or potential best-in-class medicines
- Novel, complementary mechanisms of action for the potential treatment of epilepsy & seizures
- Significant unmet need

+ Potential upcoming events

- Phase 3 data from SKYWAY study in Lennox-Gastaut syndrome (conducted by Takeda)
- Phase 3 data from SKYLINE study in Dravet syndrome (conducted by Takeda)
- Phase 1 results for OV329 assessing target engagement, safety & pharmacokinetics
- Multiple ascending dose data & pivotal formulation for GV101
- Anticipated submission of IND for OV350
- Series of potential country regulatory filings for soticlestat (conducted by Takeda)

¹ As of 3/31/23

² As of 3/31/23, on an as if converted basis



Conquering epilepsies &
brain disorders with
courageous science

